Accordingly, our previous studies also revealed that CXCL3 facilities the malignant behaviors of tumor cells in cervical cancer and prostate cancer via activation of the MAPK/ERK signaling pathway [10, 11]. This evidence concerns the gene CXCL3 and cervical carcinoma.